← All trials
NCT04391101
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- May 18, 2020
- Last posted
- May 20, 2020
- Enrollment
- 231
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University AlicanteLead sponsor
- Hospital Pablo Tobón UribeCollaborator
- University AlicanteOverall official - principal investigator
- Clínica CardiovidCollaborator
- Clínica Las AméricasCollaborator
- Hospital Joan XXIII de Tarragona, Tarragona, SpainCollaborator
- Clínica Rosario El TesoroCollaborator
- Clínica Universitaria BolivarianaCollaborator
- Universidad de AntioquiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.